SCHEMBL30765978

SCHEMBL30765978

CO[C@@H]1CO[C@H]2[C@@H]1OC[C@H]2Oc1ccc(-c2ncc(NCCCc3ccccc3)c(=O)n2CC(=O)O)cc1

nearest known ligand 0.41

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
ELANE P08246 11/20 0.41
CASP1 P29466 1/20 0.38
BCHE P06276 1/20 0.38
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
ADORA3 P0DMS8 1/20 0.36
ADORA2B P29275 1/20 0.36
KDM4E B2RXH2 1/20 0.35
ASPH Q12797 1/20 0.35
RIOX2 Q8IUF8 1/20 0.35
KDM8 Q8N371 1/20 0.35
CMA1 P23946 2/20 0.35
LMNA P02545 1/20 0.35
TP53 P04637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30765687 0.92 BCHE (0.41) ELANECASP1BCHENPC1RAB9A
SCHEMBL30765476 0.91 ELANE (0.40) ELANECASP1BCHENPC1RAB9A
SCHEMBL30765503 0.87 BCHE (0.41) BCHEKDM4EASPHRIOX2KDM8
SCHEMBL30765659 0.86 ELANE (0.39) ELANECASP1NPC1RAB9AKDM4E
SCHEMBL30765608 0.84 GAA (0.41) ELANEBCHENPC1RAB9AADORA3
SCHEMBL30766052 0.84 KLK7 (0.42) ELANEBCHE
SCHEMBL30765638 0.84 GAA (0.41) ELANEBCHEADORA3ADORA2B
SCHEMBL30765555 0.83 CASP1 (0.42) ELANECASP1
SCHEMBL30765905 0.82 ELANE (0.39) ELANECASP1NPC1RAB9AKDM4E
SCHEMBL31558528 0.81 BCHE (0.40) BCHEKDM4EASPHRIOX2KDM8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed